Insight into treatment of HIV infection from viral dynamics models
暂无分享,去创建一个
Martin A Nowak | Daniel I. S. Rosenbloom | Alison L Hill | R. Siliciano | M. Nowak | A. Hill | Robert F Siliciano | Daniel I S Rosenbloom
[1] R. Siliciano,et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells , 2003, Nature Medicine.
[2] Hulin Wu,et al. Modeling Long-Term HIV Dynamics and Antiretroviral Response: Effects of Drug Potency, Pharmacokinetics, Adherence, and Drug Resistance , 2005, Journal of acquired immune deficiency syndromes.
[3] Philippe Cluzel,et al. Uncovering scaling laws to infer multidrug response of resistant microbes and cancer cells. , 2014, Cell reports.
[4] D. Wodarz,et al. HIV–1 dynamics revisited: biphasic decay by cytotoxic T lymphocyte killing? , 2000, Proceedings of the Royal Society of London. Series B: Biological Sciences.
[5] Russell W. Anderson,et al. Direct HIV cytopathicity cannot account for CD4 decline in AIDS in the presence of homeostasis: a worst-case dynamic analysis. , 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.
[6] P. Lemey,et al. Longitudinal Genetic Characterization Reveals That Cell Proliferation Maintains a Persistent HIV Type 1 DNA Pool During Effective HIV Therapy. , 2015, The Journal of infectious diseases.
[7] M. Boffito,et al. Long-acting antiviral agents for HIV treatment , 2015, Current opinion in HIV and AIDS.
[8] Wilhelm Huisinga,et al. Drug-Class Specific Impact of Antivirals on the Reproductive Capacity of HIV , 2010, PLoS Comput. Biol..
[9] P. Volberding,et al. Effect of Short-Term Antiretroviral Therapy Interruption on Levels of Integrated HIV DNA , 2018, Journal of Virology.
[10] Troy Day,et al. A Biologist's Guide to Mathematical Modeling in Ecology and Evolution , 2007 .
[11] Jeffrey M. Gerold,et al. TLR7 agonists induce transient viremia and reduce the viral reservoir in SIV-infected rhesus macaques on antiretroviral therapy , 2018, Science Translational Medicine.
[12] Robert Langer,et al. Development of an oral once-weekly drug delivery system for HIV antiretroviral therapy , 2018, Nature Communications.
[13] M. Lederman,et al. Towards an HIV cure: a global scientific strategy , 2012, Nature Reviews Immunology.
[14] R. Siliciano,et al. Short communication: dynamic constraints on the second phase compartment of HIV-infected cells. , 2011, AIDS research and human retroviruses.
[15] A. Perelson,et al. HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time , 1996, Science.
[16] F. Maldarelli. The role of HIV integration in viral persistence: no more whistling past the proviral graveyard. , 2016, The Journal of clinical investigation.
[17] Alan S. Perelson,et al. This is an open-access article distributed under the terms of the Creative Commons Attribution Non Commercial License, which permits noncommercial use, distribution, and reproduction in other forums, provided the original authors and source are credited , 2022 .
[18] J. Sprent,et al. Homeostatic proliferation and survival of naïve and memory T cells , 2009, European journal of immunology.
[19] Martin A. Nowak,et al. Antiretroviral dynamics determines HIV evolution and predicts therapy outcome , 2012, Nature Medicine.
[20] R. Siliciano,et al. Comparative Analysis of Measures of Viral Reservoirs in HIV-1 Eradication Studies , 2013, PLoS pathogens.
[21] Alan S. Perelson,et al. Decay characteristics of HIV-1-infected compartments during combination therapy , 1997, Nature.
[22] J. Mellors,et al. Nonhuman Primate Models for HIV Cure Research , 2012, PLoS pathogens.
[23] Lin Shen,et al. A Quantitative Basis for Antiretroviral Therapy for HIV-1 Infection , 2012, Nature Medicine.
[24] Brendan B. Larsen,et al. Proliferation of cells with HIV integrated into cancer genes contributes to persistent infection , 2014, Science.
[25] Xu G. Yu,et al. Effect of analytical treatment interruption and reinitiation of antiretroviral therapy on HIV reservoirs and immunologic parameters in infected individuals , 2018, PLoS pathogens.
[26] Nancie M Archin,et al. Proviral Latency, Persistent Human Immunodeficiency Virus Infection, and the Development of Latency Reversing Agents. , 2017, The Journal of infectious diseases.
[27] Lawrence Corey,et al. Mathematical modeling of herpes simplex virus-2 suppression with pritelivir predicts trial outcomes , 2016, Science Translational Medicine.
[28] Alex Welte,et al. HIV Treatment as Prevention: Principles of Good HIV Epidemiology Modelling for Public Health Decision-Making in All Modes of Prevention and Evaluation , 2012, PLoS medicine.
[29] R. Siliciano,et al. A Critical Subset Model Provides a Conceptual Basis for the High Antiviral Activity of Major HIV Drugs , 2011, Science Translational Medicine.
[30] Martin A. Nowak,et al. Viral dynamics in human immunodeficiency virus type 1 infection , 1995, Nature.
[31] Anthony D. Kelleher,et al. HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days—Implications for HIV Remission , 2015, PLoS pathogens.
[32] Vitaly V. Ganusov,et al. Broad CTL Response in Early HIV Infection Drives Multiple Concurrent CTL Escapes , 2015, PLoS Comput. Biol..
[33] Jeffrey M. Gerold,et al. Ad26/MVA Therapeutic Vaccination with TLR7 Stimulation in SIV-Infected Rhesus Monkeys , 2016, Nature.
[34] Christian Brander,et al. Selective Escape from CD8+ T-Cell Responses Represents a Major Driving Force of Human Immunodeficiency Virus Type 1 (HIV-1) Sequence Diversity and Reveals Constraints on HIV-1 Evolution , 2005, Journal of Virology.
[35] M. Suchard,et al. The early spread and epidemic ignition of HIV-1 in human populations , 2014, Science.
[36] B. McDonald,et al. Fitness Cost of Resistance: Impact on Management , 2015 .
[37] D. Hazuda,et al. Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase , 2007, AIDS.
[38] Richard Jefferys,et al. International AIDS Society global scientific strategy: towards an HIV cure 2016 , 2016, Nature Medicine.
[39] M A Nowak,et al. Competition between zidovudine‐sensitive and zidovudine‐resistant strains of HIV , 1992, AIDS.
[40] J. Routy,et al. HIV immunotherapy comes of age: implications for prevention, treatment and cure , 2016, Expert review of clinical immunology.
[41] Melanie I. Stefan,et al. Cooperative Binding , 2013, PLoS Comput. Biol..
[42] Philip A. Eckhoff,et al. A model of HIV drug resistance driven by heterogeneities in host immunity and adherence patterns , 2013, BMC Systems Biology.
[43] Michael J. Piovoso,et al. HIV Model Parameter Estimates from Interruption Trial Data including Drug Efficacy and Reservoir Dynamics , 2012, PloS one.
[44] Florian Klein,et al. HIV-1 Integration Landscape during Latent and Active Infection , 2015, Cell.
[45] A. Perelson,et al. Quantifying antiviral activity optimizes drug combinations against hepatitis C virus infection , 2017, Proceedings of the National Academy of Sciences.
[46] E. Boritz,et al. Identification of Genetically Intact HIV-1 Proviruses in Specific CD4+ T Cells from Effectively Treated Participants. , 2017, Cell reports.
[47] A S Perelson,et al. Modeling plasma virus concentration during primary HIV infection. , 2000, Journal of theoretical biology.
[48] A. Haase,et al. Population biology of HIV-1 infection: viral and CD4+ T cell demographics and dynamics in lymphatic tissues. , 1999, Annual review of immunology.
[49] M A Nowak,et al. Viral dynamics in vivo: limitations on estimates of intracellular delay and virus decay. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[50] R. Shafer. Rationale and uses of a public HIV drug-resistance database. , 2006, The Journal of infectious diseases.
[51] Jerome H. Kim,et al. Prospective Study of Acute HIV-1 Infection in Adults in East Africa and Thailand. , 2016, The New England journal of medicine.
[52] Lin Shen,et al. Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycle , 2008, Proceedings of the National Academy of Sciences.
[53] A. Perelson,et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection , 1995, Nature.
[54] Roger Detels,et al. Plasma Viral Load and CD4+ Lymphocytes as Prognostic Markers of HIV-1 Infection , 1997, Annals of Internal Medicine.
[55] Sebastian Bonhoeffer,et al. The Role of Adherence and Retreatment in De Novo Emergence of MDR-TB , 2016, PLoS Comput. Biol..
[56] D. Hollomon,et al. Fungicide resistance in plant pathogens : principles and a guide to practical management , 2015 .
[57] Libin Rong,et al. Mathematical modeling of viral kinetics under immune control during primary HIV-1 infection. , 2009, Journal of theoretical biology.
[58] Lin Shen,et al. Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs , 2008, Nature Medicine.
[59] M. Lederman,et al. Origin of Rebound Plasma HIV Includes Cells with Identical Proviruses That Are Transcriptionally Active before Stopping of Antiretroviral Therapy , 2015, Journal of Virology.
[60] A. Perelson,et al. Contribution of Follicular Dendritic Cells to Persistent HIV Viremia , 2013, Journal of Virology.
[61] Alan S. Perelson,et al. Current Estimates for HIV-1 Production Imply Rapid Viral Clearance in Lymphoid Tissues , 2010, PLoS Comput. Biol..
[62] G. Pantaleo,et al. The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo , 2015, PLoS pathogens.
[63] Feng Fu,et al. Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1 , 2014, Proceedings of the National Academy of Sciences.
[64] Luc Montagnier,et al. The discovery of HIV as the cause of AIDS. , 2003, The New England journal of medicine.
[65] Alan S. Perelson,et al. Estimation of the Initial Viral Growth Rate and Basic Reproductive Number during Acute HIV-1 Infection , 2010, Journal of Virology.
[66] R. Lempicki,et al. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[67] R. Siliciano,et al. Novel Single-Cell-Level Phenotypic Assay for Residual Drug Susceptibility and Reduced Replication Capacity of Drug-Resistant Human Immunodeficiency Virus Type 1 , 2004, Journal of Virology.
[68] Jinyan Liu,et al. Rapid Seeding of the Viral Reservoir Prior to SIV Viremia in Rhesus Monkeys , 2014, Nature.
[69] A. Perelson,et al. Complex patterns of viral load decay under antiretroviral therapy: influence of pharmacokinetics and intracellular delay. , 2004, Journal of theoretical biology.
[70] Jeffrey M. Gerold,et al. Expanded cellular clones carrying replication-competent HIV-1 persist, wax, and wane , 2018, Proceedings of the National Academy of Sciences.
[71] A. Hill. Mathematical Models of HIV Latency. , 2018, Current topics in microbiology and immunology.
[72] J. Margolick,et al. Consistent Viral Evolutionary Changes Associated with the Progression of Human Immunodeficiency Virus Type 1 Infection , 1999, Journal of Virology.
[73] A. Chakraborty,et al. Enhanced clearance of HIV-1–infected cells by broadly neutralizing antibodies against HIV-1 in vivo , 2016, Science.
[74] Alan S. Perelson,et al. A Novel Antiviral Intervention Results in More Accurate Assessment of Human Immunodeficiency Virus Type 1 Replication Dynamics and T-Cell Decay In Vivo , 2003, Journal of Virology.
[75] Sebastian Bonhoeffer,et al. Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis , 1999, The Lancet.
[76] M A Nowak,et al. Antigenic diversity thresholds and the development of AIDS. , 1991, Science.
[77] R. Siliciano,et al. Biphasic decay of latently infected CD4+ T cells in acute human immunodeficiency virus type 1 infection. , 2000, The Journal of infectious diseases.
[78] R. Paredes,et al. HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection , 2001, AIDS.
[79] S. Lewin,et al. Relationship between Measures of HIV Reactivation and Decline of the Latent Reservoir under Latency-Reversing Agents , 2017, Journal of Virology.
[80] M. Gottesman,et al. Targeting the Achilles Heel of Multidrug-Resistant Cancer by Exploiting the Fitness Cost of Resistance , 2014, Chemical reviews.
[81] Sarah Palmer,et al. Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial. , 2014, The lancet. HIV.
[82] A. Perelson,et al. Early HIV RNA decay during raltegravir-containing regimens exhibits two distinct subphases (1a and 1b) , 2015, AIDS.
[83] Rustom Antia,et al. Understanding the Slow Depletion of Memory CD4+ T Cells in HIV Infection , 2007, PLoS medicine.
[84] Ben Berkhout,et al. The HIV RNA setpoint theory revisited , 2007, Retrovirology.
[85] A. Trkola,et al. HIV rebounds from latently infected cells, rather than from continuing low-level replication , 2008, Proceedings of the National Academy of Sciences.
[86] J. Mellors,et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy , 2008, Proceedings of the National Academy of Sciences.
[87] Lin Shen,et al. Dose–response curve slope is a missing dimension in the analysis of HIV-1 drug resistance , 2011, Proceedings of the National Academy of Sciences.
[88] J. Eron,et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy , 2012, Nature.
[89] S. Bonhoeffer,et al. Assessing the impact of adherence to anti-retroviral therapy on treatment failure and resistance evolution in HIV , 2012, Journal of The Royal Society Interface.
[90] R. Siliciano,et al. Constraints on the dominant mechanism for HIV viral dynamics in patients on raltegravir , 2009, Antiviral therapy.
[91] M. von Kleist,et al. Top-down and bottom-up modeling in system pharmacology to understand clinical efficacy: An example with NRTIs of HIV-1. , 2016, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[92] A. Hill. Modeling HIV persistence and cure studies , 2018, Current opinion in HIV and AIDS.
[93] Michael S. Seaman,et al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117 , 2015, Nature.
[94] L M Wahl,et al. Adherence and drug resistance: predictions for therapy outcome , 2000, Proceedings of the Royal Society of London. Series B: Biological Sciences.
[95] Nancie M Archin,et al. Precise Quantitation of the Latent HIV-1 Reservoir: Implications for Eradication Strategies. , 2015, The Journal of infectious diseases.
[96] D. Tough,et al. Rapid Turnover of Effector–Memory CD4+ T Cells in Healthy Humans , 2004, The Journal of experimental medicine.
[97] Eduardo D Sontag,et al. Mechanism-independent method for predicting response to multidrug combinations in bacteria , 2012, Proceedings of the National Academy of Sciences.
[98] J. Schiffer,et al. Anti-proliferative therapy for HIV cure: a compound interest approach , 2017, bioRxiv.
[99] A. Hill,et al. The possible effects of the aggregation of the molecules of haemoglobin on its dissociation curves , 1910 .
[100] M. Boily,et al. The HIV Modes of Transmission model: a systematic review of its findings and adherence to guidelines , 2014, Journal of the International AIDS Society.
[101] M. Wainberg,et al. A Mathematical Model to Predict HIV Virological Failure and Elucidate the Role of Lymph Node Drug Penetration , 2017, CPT: pharmacometrics & systems pharmacology.
[102] G. V. Van Zyl,et al. HIV evolution and diversity in ART-treated patients , 2018, Retrovirology.
[103] Martin A. Nowak,et al. Life cycle synchronization is a viral drug resistance mechanism , 2018, PLoS Comput. Biol..
[104] A S Perelson,et al. Dynamics of HIV-1 and CD4+ lymphocytes in vivo. , 1997, AIDS.
[105] J. Borghans,et al. Lymphocyte kinetics in health and disease. , 2009, Trends in immunology.
[106] Winnie Gimode,et al. Fitness cost of resistance for lumefantrine and piperaquine-resistant Plasmodium berghei in a mouse model , 2015, Malaria Journal.
[107] W. Greco,et al. The search for synergy: a critical review from a response surface perspective. , 1995, Pharmacological reviews.
[108] A. Perelson. Modelling viral and immune system dynamics , 2002, Nature Reviews Immunology.
[109] R. Colgrove,et al. A combinatorial ledge: reverse transcriptase fidelity, total body viral burden, and the implications of multiple-drug HIV therapy for the evolution of antiviral resistance. , 1999, Antiviral research.
[110] M A Nowak,et al. Virus dynamics and drug therapy. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[111] M. Lederman,et al. Three distinct phases of HIV-1 RNA decay in treatment-naive patients receiving raltegravir-based antiretroviral therapy: ACTG A5248. , 2013, The Journal of infectious diseases.
[112] Sarah B. Laskey,et al. Replication-Competent Noninduced Proviruses in the Latent Reservoir Increase Barrier to HIV-1 Cure , 2013, Cell.
[113] R. Siliciano,et al. The Latent Reservoir for HIV-1: How Immunologic Memory and Clonal Expansion Contribute to HIV-1 Persistence , 2016, The Journal of Immunology.
[114] R. Siliciano,et al. The latent reservoir for HIV-1 in resting CD4+ T cells: a barrier to cure , 2006, Current opinion in HIV and AIDS.
[115] A. Perelson,et al. Influence of delayed viral production on viral dynamics in HIV-1 infected patients. , 1998, Mathematical biosciences.
[116] P. Kaye. Infectious diseases of humans: Dynamics and control , 1993 .
[117] D. Margolis,et al. Curing HIV: Pharmacologic approaches to target HIV-1 latency. , 2011, Annual review of pharmacology and toxicology.
[118] J. Stover. Influence of Mathematical Modeling of HIV and AIDS on Policies and Programs in the Developing World , 2000, Sexually transmitted diseases.
[119] Daniel R Kuritzkes,et al. Treatment with integrase inhibitor suggests a new interpretation of HIV RNA decay curves that reveals a subset of cells with slow integration , 2017, PLoS pathogens.
[120] Alan S. Perelson,et al. Fitness Costs and Diversity of the Cytotoxic T Lymphocyte (CTL) Response Determine the Rate of CTL Escape during Acute and Chronic Phases of HIV Infection , 2011, Journal of Virology.
[121] Simon Wain-Hobson. Virus Dynamics: Mathematical Principles of Immunology and Virology , 2001, Nature Medicine.
[122] R Brookmeyer,et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. , 1997, Science.
[123] A. Wong,et al. The fitness costs of antibiotic resistance mutations , 2014, Evolutionary applications.
[124] M. Gottlieb,et al. Pneumocystis pneumonia--Los Angeles. , 2006, MMWR. Morbidity and mortality weekly report.
[125] Uri Alon,et al. Prediction of multidimensional drug dose responses based on measurements of drug pairs , 2016, Proceedings of the National Academy of Sciences.
[126] S. Hughes,et al. B-108 Specific HIV integration sites are linked to clonal expansion and persistence of infected cells , 2016 .
[127] R. ffrench-Constant,et al. Does resistance really carry a fitness cost? , 2017, Current opinion in insect science.
[128] Jessica M Conway,et al. Post-treatment control of HIV infection , 2015, Proceedings of the National Academy of Sciences.
[129] Christian L. Althaus,et al. Dynamics of Immune Escape during HIV/SIV Infection , 2008, PLoS Comput. Biol..
[130] E. Rosenberg,et al. Clonal expansion of genome-intact HIV-1 in functionally polarized Th1 CD4+ T cells , 2017, The Journal of clinical investigation.
[131] S. Hughes,et al. Specific HIV integration sites are linked to clonal expansion and persistence of infected cells , 2014, Science.
[132] Andrew N. Phillips,et al. Reduction of HIV Concentration During Acute Infection: Independence from a Specific Immune Response , 1996, Science.
[133] Ruy M Ribeiro,et al. Modeling the within-host dynamics of HIV infection , 2013, BMC Biology.
[134] R. Paredes,et al. Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression , 2000, AIDS.
[135] James O. Lloyd-Smith,et al. Rational Design and Adaptive Management of Combination Therapies for Hepatitis C Virus Infection , 2014, bioRxiv.